These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8780859)

  • 21. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
    Hiemke C; Peled A; Jabarin M; Hadjez J; Weigmann H; Härtter S; Modai I; Ritsner M; Silver H
    J Clin Psychopharmacol; 2002 Oct; 22(5):502-6. PubMed ID: 12352274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial.
    Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H
    Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients.
    Silver H; Susser E; Danovich L; Bilker W; Youdim M; Goldin V; Weinreb O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):573-84. PubMed ID: 21208484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia.
    Iyo M; Shirayama Y; Watanabe H; Fujisaki M; Miyatake R; Fukami G; Shiina A; Nakazato M; Shiraishi T; Ookami T; Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1072-3. PubMed ID: 18262707
    [No Abstract]   [Full Text] [Related]  

  • 25. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia.
    Taiminen TJ; Syvälahti E; Saarijärvi S; Niemi H; Lehto H; Ahola V; Salokangas RK
    Int Clin Psychopharmacol; 1997 Jan; 12(1):31-5. PubMed ID: 9179631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
    Preskorn SH
    J Psychiatr Pract; 2005 May; 11(3):192-6. PubMed ID: 15920392
    [No Abstract]   [Full Text] [Related]  

  • 27. The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.
    Einoch R; Weinreb O; Mandiuk N; Youdim MBH; Bilker W; Silver H
    Eur Neuropsychopharmacol; 2017 May; 27(5):470-483. PubMed ID: 28410959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluvoxamine for psychosis in Alzheimer's disease.
    Levkovitz Y; Bloch Y; Kaplan D; Diskin A; Abramovitchi I
    J Nerv Ment Dis; 2001 Feb; 189(2):126-9. PubMed ID: 11225688
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacotherapy of chronic schizophrenic psychoses--neuroleptic plus serotonin reuptake inhibitor?].
    Salzmann E; Eikelmann B
    Psychiatr Prax; 1997 Sep; 24(5):253. PubMed ID: 9417552
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.
    Ständer S; Böckenholt B; Schürmeyer-Horst F; Weishaupt C; Heuft G; Luger TA; Schneider G
    Acta Derm Venereol; 2009; 89(1):45-51. PubMed ID: 19197541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks.
    Albert R; Ebert D
    J Clin Psychiatry; 1996 Apr; 57(4):176. PubMed ID: 8601556
    [No Abstract]   [Full Text] [Related]  

  • 34. Suicidal risk during controlled clinical investigations of fluvoxamine.
    Letizia C; Kapik B; Flanders WD
    J Clin Psychiatry; 1996 Sep; 57(9):415-21. PubMed ID: 9746450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trichotilliomania responding to low-dose fluvoxamine.
    Ikenouchi-Sugita A; Yoshimura R; Ueda N; Nakamura J
    Psychiatry Clin Neurosci; 2009 Oct; 63(5):701-2. PubMed ID: 19788633
    [No Abstract]   [Full Text] [Related]  

  • 36. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
    Stein MB; Fyer AJ; Davidson JR; Pollack MH; Wiita B
    Am J Psychiatry; 1999 May; 156(5):756-60. PubMed ID: 10327910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
    [No Abstract]   [Full Text] [Related]  

  • 38. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
    McDougle CJ; Naylor ST; Cohen DJ; Volkmar FR; Heninger GR; Price LH
    Arch Gen Psychiatry; 1996 Nov; 53(11):1001-8. PubMed ID: 8911223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors.
    Honda M; Uchida K; Tanabe M; Ono H
    Neuropharmacology; 2006 Sep; 51(4):866-72. PubMed ID: 16846619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms.
    Silver H; Aharon N; Kaplan A
    Schizophr Bull; 2003; 29(3):541-6. PubMed ID: 14609247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.